File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fonc.2020.00658
- Scopus: eid_2-s2.0-85084531705
- WOS: WOS:000556336300001
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: More than a metabolic enzyme: MTHFD2 as a novel target for anticancer therapy?
Title | More than a metabolic enzyme: MTHFD2 as a novel target for anticancer therapy? |
---|---|
Authors | |
Keywords | cancer metabolism one carbon metabolism metabolic enzyme oncogenicity epigenetic modification |
Issue Date | 2020 |
Publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology |
Citation | Frontiers in Oncology, 2020, v. 10, p. article no. 658 How to Cite? |
Abstract | The bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase (MTHFD2) is a mitochondrial one-carbon folate metabolic enzyme whose role in cancer was not known until recently. MTHFD2 is highly expressed in embryos and a wide range of tumors but has low or absent expression in most adult differentiated tissues. Elevated MTHFD2 expression is associated with poor prognosis in both hematological and solid malignancy. Its depletion leads to suppression of multiple malignant phenotypes including proliferation, invasion, migration, and induction of cancer cell death. The non-metabolic functions of this enzyme, especially in cancers, have thus generated considerable research interests. This review summarizes current knowledge on both the metabolic functions and non-enzymatic roles of MTHFD2. Its expression, potential functions, and regulatory mechanism in cancers are highlighted. The development of MTHFD2 inhibitors and their implications in pre-clinical models are also discussed. |
Persistent Identifier | http://hdl.handle.net/10722/282242 |
ISSN | 2023 Impact Factor: 3.5 2023 SCImago Journal Rankings: 1.066 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | ZHU, Z | - |
dc.contributor.author | Leung, GKK | - |
dc.date.accessioned | 2020-05-05T14:32:37Z | - |
dc.date.available | 2020-05-05T14:32:37Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Frontiers in Oncology, 2020, v. 10, p. article no. 658 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/10722/282242 | - |
dc.description.abstract | The bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase (MTHFD2) is a mitochondrial one-carbon folate metabolic enzyme whose role in cancer was not known until recently. MTHFD2 is highly expressed in embryos and a wide range of tumors but has low or absent expression in most adult differentiated tissues. Elevated MTHFD2 expression is associated with poor prognosis in both hematological and solid malignancy. Its depletion leads to suppression of multiple malignant phenotypes including proliferation, invasion, migration, and induction of cancer cell death. The non-metabolic functions of this enzyme, especially in cancers, have thus generated considerable research interests. This review summarizes current knowledge on both the metabolic functions and non-enzymatic roles of MTHFD2. Its expression, potential functions, and regulatory mechanism in cancers are highlighted. The development of MTHFD2 inhibitors and their implications in pre-clinical models are also discussed. | - |
dc.language | eng | - |
dc.publisher | Frontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/oncology | - |
dc.relation.ispartof | Frontiers in Oncology | - |
dc.rights | This Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission. | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | cancer metabolism | - |
dc.subject | one carbon metabolism | - |
dc.subject | metabolic enzyme | - |
dc.subject | oncogenicity | - |
dc.subject | epigenetic modification | - |
dc.title | More than a metabolic enzyme: MTHFD2 as a novel target for anticancer therapy? | - |
dc.type | Article | - |
dc.identifier.email | Leung, GKK: gkkleung@hku.hk | - |
dc.identifier.authority | Leung, GKK=rp00522 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.3389/fonc.2020.00658 | - |
dc.identifier.scopus | eid_2-s2.0-85084531705 | - |
dc.identifier.hkuros | 309854 | - |
dc.identifier.volume | 10 | - |
dc.identifier.spage | article no. 658 | - |
dc.identifier.epage | article no. 658 | - |
dc.identifier.isi | WOS:000556336300001 | - |
dc.publisher.place | Switzerland | - |
dc.identifier.issnl | 2234-943X | - |